

AGENDA

- | | |
|------------|--|
| 10:00 a.m. | Welcome and opening remarks
Michael Engsig, Nykode Chief Executive Officer |
| 10:10 a.m. | VB10.16 program update: where we have come from, new learnings, and future plans
Klaus Edvardsen, Nykode Chief Development Officer |
| 10:30 a.m. | The treatment landscape for Cervical Cancer and perspectives on VB10.16
Dr. Bradley Monk, MD, FACS, FACOG
Vice President and Member Board of Directors GOG-Foundation
Co-director GOG-Partners
Director, Principal Investigator, Community Research Development, HonorHealth Research Institute
Professor, Division of Gynecologic Oncology, University of Arizona College of Medicine |
| 10:50 a.m. | VB10.NEO program update (in partnership with Roche / Genentech), including longer-term follow-up data from Phase 1/2
Klaus Edvardsen, Nykode Chief Development Officer |
| 11:10 a.m. | Q&A Session |
| 11:30 a.m. | Break |
| 11:50 a.m. | Research and Innovation update: unlocking the power of the Nykode platform in oncology and autoimmunity
Mikkel Wandahl Pedersen, Nykode Chief Scientific Officer |
| 12:20 p.m. | The Nykode Business Model
Agnete B. Fredriksen, Nykode Chief Business Officer and Co-founder |
| 12:30 p.m. | Final remarks
Michael Engsig, Nykode Chief Executive Officer |
| 12:40 p.m. | Q&A Session |
| 1.00 p.m. | Lunch & Networking |